Novo makes a gene editing move
Today’s collaboration with Life Edit is a return to the Danish group’s familiar small, early-stage deal strategy.
A blockbuster year could be building
If forecasts prove accurate 2023 could be the biggest year for blockbuster launches for some time.
Gene editing: overhyped or unstoppable tide?
A new report from Evaluate Vantage looks at recent developments in gene editing and delivery.
Finding the big spenders beyond big pharma
Developers like Vertex, Regeneron and Novo Nordisk have significantly upped R&D spending in recent years, and become important acquirers.
Big pharma holds steady on research spending
R&D spending by the world’s largest drug makers flatlined in 2022, with Roche footing the biggest bill and Astrazeneca the fastest accelerator.
AACR 2023 – more hope for Moderna’s neoantigen immunotherapy
After Moderna/Merck & Co’s December splash, full data from Keynote-942 stand up to scrutiny.
